Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. - Wikidata - awgldk - TriplyDB

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q37019838

about

Endothelin-dependent vasoconstriction in human uterine artery: application to preeclampsia.

P2860

Q33813477-EBAA1FA6-CD37-4D42-A9EC-9434E7BC1884

P2860

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.

http://www.wikidata.org/entity/Q37019838

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Optimizing endothelin receptor ...... lmonary arterial hypertension.

@en

Optimizing endothelin receptor ...... lmonary arterial hypertension.

@nl

type

label

Optimizing endothelin receptor ...... lmonary arterial hypertension.

@en

Optimizing endothelin receptor ...... lmonary arterial hypertension.

@nl

prefLabel

Optimizing endothelin receptor ...... lmonary arterial hypertension.

@en

Optimizing endothelin receptor ...... lmonary arterial hypertension.

@nl

P1433

Q37019838-FBE8A433-9BE3-404D-BCE2-745F4CB37B97

P1476

Q37019838-458654A7-A8A7-48D3-8E56-9AC2F5ADE6B6

P2093

Q37019838-50547C6F-A5F5-4B69-A7D2-5D561839CA5F

Q37019838-63FA0ECA-C32E-470F-8B62-58DCE14CF9DC

P2860

Q37019838-04C2A737-DEBE-4486-98AB-99F28E1242DD

Q37019838-0BC16721-37B9-495B-ACDF-BBA15F0CD076

Q37019838-10DB15A1-498F-439D-BD73-40FD7E46673C

Q37019838-19CAC9DE-6CFE-42EE-A8AC-78140ACCD265

Q37019838-1C19C192-9C70-4DBD-AAB8-2E231D843F0F

Q37019838-2102F586-5870-4E55-B24C-78D277EF1764

Q37019838-230382B5-0D8E-4F21-A276-B7769FD354A6

Q37019838-2F1BD5D3-1563-4877-8B67-CBB2C241454B

Q37019838-33CA72E2-02B3-483A-9E13-E92F41EB64E2

Q37019838-420A2628-499A-4662-8F20-2D163C4441D4

P304

Q37019838-3954B30A-C237-438B-A845-F85797165A36

P31

Q37019838-D738EFCE-A6FF-421C-BA17-4F93A85F9139

P356

Q37019838-6E740E1B-818F-4076-8018-4EA0A586291E

P407

Q37019838-E19B00DA-31CA-488A-9AEE-51E4D07B9AA0

P433

Q37019838-75331880-D6E6-4350-A6A1-7641FC1628AE

P478

Q37019838-DED7F4E6-9162-4930-97AA-29DCDA237FDB

P577

Q37019838-F4AAB426-01DF-431C-AF84-DB92F498B34D

P698

Q37019838-737CBF1C-FA69-4C65-BB5F-14DC0FBFA0E8

P921

Q37019838-31BA14ED-6EBE-4C3A-8DE7-DAF742095964

Q37019838-48D06BCF-9611-4A3D-AC4A-0C7758D90956

Q37019838-94B8F278-B5A3-4A4B-89B8-D08401626BFA

P932

Q37019838-2C801D0C-C532-4EFD-A00A-E327A539C7F3

P356

P1433

Vascular Health and Risk Management

P1476

Optimizing endothelin receptor ...... ulmonary arterial hypertension

@en

P2093

Ioana R Preston

http://www.w3.org/2001/XMLSchema#string

M Kathryn Steiner

http://www.w3.org/2001/XMLSchema#string

P2860

Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease

Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal rat

Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension.

Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.

Sitaxsentan therapy for pulmonary arterial hypertension.

Survival with first-line bosentan in patients with primary pulmonary hypertension.

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.

Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

P304

943-952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/VHRM.S2270

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19183742

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary hypertension

mechanism of action

arterial hypertension

P932

2605321

http://www.w3.org/2001/XMLSchema#string